Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

Back

ESC Premium Access

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

Session: Clinical Trial Update 2

Topic: CAD and comorbidities

Speaker: Professor S. Nicholls (Melbourne, AU)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Stephen Nicholls

Monash University, Melbourne (Australia)

53 presentations

5 followers

5 more presentations in this session

Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen

Speaker: Professor S. Nissen (Cleveland, US)

Access

Slides

Video

Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk

Speaker: Professor T. Pedersen (Oslo, NO)

Access

Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial

Speaker: Professor E. Lonn (Hamilton, CA)

One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.

Speaker: Doctor V. Roolvink (Zwolle, NL)

Access the full session

Clinical Trial Update 2

Speakers: Professor S. Nicholls, Professor S. Nissen, Professor T. Pedersen, Professor S. Verma, Professor E. Lonn...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources